1. Goldin A, Schepartz SA, Venditti JM, Devita Jr VT: Historical development and current strategy of the National Cancer Institute drug development program. In: DeVita VT, Busch H (eds) Methods in Cancer Research, XVI. New York Academic Press, 1979, pp 165–245
2. Goldin A, Venditti JM: The new NCI screen and its implications for clinical evaluations. In: Carter SK, Sakurai Y (eds) Recent Results in Cancer Research, 70. Springer-Verlag, 1980, pp 5–20
3. Venditti JM: Preclinical drug development: rationale and methods. Semin Oncol 8: 349–361, 1981
4. Venditti JM: Wesley RA, Plowman J: Current NCI preclinical antitumor screening in vivo: Results of tumor panel screening, 1976–1982, and future directions. In: Garattini S, Goldin A, Hawking F (eds) Advance in Pharmacology and Chemotherapy, 20. Academic Press, Orlando FL, 1984, pp 1–20
5. Driscoll JS: The preclinical new drug research program of the National Cancer Institute. Cancer Treat Rep 68: 63–76, 1984